Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 3
1953 1
1956 1
1960 1
1961 1
1963 1
1971 2
1973 7
1974 2
1975 2
1977 4
1979 2
1980 2
1981 5
1982 3
1983 3
1984 2
1985 4
1986 10
1987 11
1988 15
1989 20
1990 35
1991 35
1992 35
1993 34
1994 44
1995 27
1996 35
1997 39
1998 41
1999 49
2000 39
2001 40
2002 35
2003 49
2004 62
2005 59
2006 61
2007 60
2008 62
2009 73
2010 74
2011 74
2012 112
2013 129
2014 198
2015 214
2016 213
2017 217
2018 252
2019 245
2020 260
2021 313
2022 298
2023 282
2024 129

Text availability

Article attribute

Article type

Publication date

Search Results

3,536 results

Results by year

Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 20Oliveri, 20Conti
Page 1
HERIZON-GEA-01: Zanidatamab + chemo tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma.
Tabernero J, Shen L, Elimova E, Ku G, Liu T, Shitara K, Lin X, Boyken L, Li H, Grim J, Ajani J. Tabernero J, et al. Future Oncol. 2022 Sep;18(29):3255-3266. doi: 10.2217/fon-2022-0595. Epub 2022 Aug 24. Future Oncol. 2022. PMID: 36000541 Free article.
Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor activity in early phase studies in multiple cancers, including GEA. Preliminary data suggest that dual targeting of the HER2 and PD-1 pa …
Zanidatamab and tislelizumab are novel monoclonal antibodies targeting HER2 and PD-1, respectively, and have shown encouraging antitumor act …
Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers.
Ehmann S, Sassine D, Straubhar AM, Praiss AM, Aghajanian C, Alektiar KM, Broach V, Cadoo KA, Jewell EL, Boroujeni AM, Kyi C, Leitao MM, Mueller JJ, Murali R, Bhaloo SI, O'Cearbhaill RE, Park KJ, Sonoda Y, Weigelt B, Zamarin D, Abu-Rustum N, Friedman CF. Ehmann S, et al. Gynecol Oncol. 2022 Dec;167(3):458-466. doi: 10.1016/j.ygyno.2022.10.003. Epub 2022 Oct 15. Gynecol Oncol. 2022. PMID: 36253302 Free PMC article.
OBJECTIVES: Gastric-type endocervical adenocarcinoma (GEA) is a rare form of cervical cancer not associated with human papilloma virus (HPV) infection. We summarize our experience with GEA at a large cancer center. METHODS: Clinical and demographic information on al …
OBJECTIVES: Gastric-type endocervical adenocarcinoma (GEA) is a rare form of cervical cancer not associated with human papilloma viru …
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. Bartley AN, et al. J Clin Oncol. 2017 Feb;35(4):446-464. doi: 10.1200/JCO.2016.69.4836. Epub 2016 Nov 14. J Clin Oncol. 2017. PMID: 28129524
Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of …
Context ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy fo …
HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Bartley AN, Washington MK, Ventura CB, Ismaila N, Colasacco C, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. Bartley AN, et al. Arch Pathol Lab Med. 2016 Dec;140(12):1345-1363. doi: 10.5858/arpa.2016-0331-CP. Epub 2016 Nov 14. Arch Pathol Lab Med. 2016. PMID: 27841667 Free article.
CONTEXT: - ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment …
CONTEXT: - ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy …
Gastric-type Endocervical Adenocarcinoma: Comprehensive Cytopathological Analysis and Comparison With Usual-type Endocervical Adenocarcinoma.
Cho H, Park S, Kim HS. Cho H, et al. In Vivo. 2023 May-Jun;37(3):1173-1181. doi: 10.21873/invivo.13192. In Vivo. 2023. PMID: 37103100 Free PMC article. Review.
BACKGROUND/AIM: Gastric-type endocervical adenocarcinoma (GEA) is a rare but distinct histological type of gynecological malignancy. This study aimed to conduct a comprehensive analysis of the cytological features of GEA. PATIENTS AND METHODS: We reviewed 18 cytolog …
BACKGROUND/AIM: Gastric-type endocervical adenocarcinoma (GEA) is a rare but distinct histological type of gynecological malignancy. …
Progress and challenges in gastroesophageal cancer.
Serra O, Smyth EC, Lordick F. Serra O, et al. Curr Probl Cancer. 2020 Dec;44(6):100590. doi: 10.1016/j.currproblcancer.2020.100590. Epub 2020 May 5. Curr Probl Cancer. 2020. PMID: 32451067 Review.
Gastroesophageal adenocarcinoma (GEA) is a challenging disease; most GEA patients do not live for more than a year after a diagnosis of advanced disease. ...The role of hetergeneity in GEA outcomes is reviewed and we discuss intra- and interpatient heterogene …
Gastroesophageal adenocarcinoma (GEA) is a challenging disease; most GEA patients do not live for more than a year after a dia …
Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma.
Augustin JE, Soussan P, Bass AJ. Augustin JE, et al. Ann Oncol. 2022 Nov;33(11):1134-1148. doi: 10.1016/j.annonc.2022.08.001. Epub 2022 Aug 10. Ann Oncol. 2022. PMID: 35963482 Free article. Review.
ERBB2 is the most prominent therapeutic target in gastroesophageal adenocarcinoma (GEA). For two decades, trastuzumab was the only treatment available for GEA overexpressing ERBB2. Several drugs showing evidence of efficacy over or in complement to trastuzumab in br …
ERBB2 is the most prominent therapeutic target in gastroesophageal adenocarcinoma (GEA). For two decades, trastuzumab was the only tr …
[The diaphragm].
Orozco-Levi M, Gea J. Orozco-Levi M, et al. Arch Bronconeumol. 1997 Sep;33(8):399-411. doi: 10.1016/s0300-2896(15)30567-6. Arch Bronconeumol. 1997. PMID: 9376941 Review. Spanish. No abstract available.
Emerging targets in gastroesophageal adenocarcinoma: what the future looks like.
Petrillo A, Smyth EC, van Laarhoven HWM. Petrillo A, et al. Ther Adv Med Oncol. 2023 May 13;15:17588359231173177. doi: 10.1177/17588359231173177. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37197225 Free PMC article. Review.
Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in treating metastatic diseases. ...Beyond immunotherapy, several attempts were made to improve patient survival by understanding the molecular mec …
Gastroesophageal adenocarcinoma (GEA) is a heterogeneous disease with a poor prognosis. Chemotherapy has been the cornerstone in trea …
Sporotrichosis: From KOH to Molecular Biology.
Arenas R, Sánchez-Cardenas CD, Ramirez-Hobak L, Ruíz Arriaga LF, Vega Memije ME. Arenas R, et al. J Fungi (Basel). 2018 May 23;4(2):62. doi: 10.3390/jof4020062. J Fungi (Basel). 2018. PMID: 29882883 Free PMC article. Review.
3,536 results